Data from vitro and clinical studies also suggested that the activation of CXCL8/CXCR1/2 signal axis is an important factor in regulating the immune microenvironment of colon cancer and leading to less benefit of ICIs treatment in colon cancer [8,9,10]. The gene discussed is CXCR1; the disease is malignant colon neoplasm.